About Belite BioADR
Belite Bio (NASDAQ:BLTE) is a biotechnology firm focused on developing therapeutic drugs for the treatment of eye diseases and metabolic disorders. Primarily operating in the research and development sector, the company is dedicated to advancing its portfolio of innovative treatments through clinical trials, with a keen eye on addressing unmet medical needs. Among its key projects are treatments aimed at tackling Age-related Macular Degeneration (AMD) and Stargardt Disease, highlighting its commitment to improving quality of life for patients with serious conditions. Belite Bio's objectives include the successful progress of their drug candidates through regulatory approvals, aiming for commercialization to make a significant impact on healthcare.
Snapshot
Operations
Produtos e/ou serviços de Belite BioADR
- LBS-008, a once-a-day oral therapy for the treatment of Stargardt Disease, aiming to slow down vision loss.
- LBS-009, an investigational treatment focused on Best disease and other macular degenerations.
- Development of advanced treatments for Geographic Atrophy, targeting age-related macular degeneration.
- Research into therapies for Dry Age-Related Macular Degeneration (Dry AMD), seeking to prevent or slow progression.
- Initiatives aimed at tackling Inherited Retinal Diseases (IRDs), with a focus on genetic therapies.
- Pipeline expansion into Wet Age-Related Macular Degeneration (Wet AMD), exploring new drug candidates.
equipe executiva do Belite BioADR
- Dr. Yu-Hsin Lin M.B.A., Ph.D.Chairman of the Board of Directors & CEO
- Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A.CFO & Director
- Dr. Nathan L. Mata Ph.D.Chief Scientific Officer
- Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D.Chief Medical Officer